543 related articles for article (PubMed ID: 24644287)
1. The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.
Wilhelmsen K; Khakpour S; Tran A; Sheehan K; Schumacher M; Xu F; Hellman J
J Biol Chem; 2014 May; 289(19):13079-100. PubMed ID: 24644287
[TBL] [Abstract][Full Text] [Related]
2.
Lawton SK; Xu F; Tran A; Wong E; Prakash A; Schumacher M; Hellman J; Wilhelmsen K
J Immunol; 2017 Aug; 199(4):1465-1475. PubMed ID: 28701511
[No Abstract] [Full Text] [Related]
3. Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine.
Ross HR; Gilmore AJ; Connor M
Br J Pharmacol; 2009 Mar; 156(5):740-50. PubMed ID: 19226289
[TBL] [Abstract][Full Text] [Related]
4. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors.
Marinelli S; Di Marzo V; Florenzano F; Fezza F; Viscomi MT; van der Stelt M; Bernardi G; Molinari M; Maccarrone M; Mercuri NB
Neuropsychopharmacology; 2007 Feb; 32(2):298-308. PubMed ID: 16760924
[TBL] [Abstract][Full Text] [Related]
5. Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide.
Price TJ; Patwardhan A; Akopian AN; Hargreaves KM; Flores CM
Br J Pharmacol; 2004 Apr; 141(7):1118-30. PubMed ID: 15006899
[TBL] [Abstract][Full Text] [Related]
6. Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret.
Sharkey KA; Cristino L; Oland LD; Van Sickle MD; Starowicz K; Pittman QJ; Guglielmotti V; Davison JS; Di Marzo V
Eur J Neurosci; 2007 May; 25(9):2773-82. PubMed ID: 17459108
[TBL] [Abstract][Full Text] [Related]
7. Cannabinoids inhibit peptidoglycan-induced phosphorylation of NF-κB and cell growth in U87MG human malignant glioma cells.
Echigo R; Sugimoto N; Yachie A; Ohno-Shosaku T
Oncol Rep; 2012 Oct; 28(4):1176-80. PubMed ID: 22842590
[TBL] [Abstract][Full Text] [Related]
8. Long lasting effects of chronic WIN55,212-2 treatment on mesostriatal dopaminergic and cannabinoid systems in the rat brain.
Perdikaris P; Tsarouchi M; Fanarioti E; Natsaridis E; Mitsacos A; Giompres P
Neuropharmacology; 2018 Feb; 129():1-15. PubMed ID: 29113897
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.
García-Arencibia M; González S; de Lago E; Ramos JA; Mechoulam R; Fernández-Ruiz J
Brain Res; 2007 Feb; 1134(1):162-70. PubMed ID: 17196181
[TBL] [Abstract][Full Text] [Related]
10. Suppression of outward K⁺ currents by WIN55212-2 in rat retinal ganglion cells is independent of CB1/CB2 receptors.
Zhang CQ; Wu HJ; Wang SY; Yin S; Lu XJ; Miao Y; Wang XH; Yang XL; Wang Z
Neuroscience; 2013 Dec; 253():183-93. PubMed ID: 24013008
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of interleukin-1β-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2.
Scholl A; Ivanov I; Hinz B
Oncotarget; 2016 Sep; 7(38):61438-61457. PubMed ID: 27556861
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoids Stimulate the TRP Channel-Dependent Release of Both Serotonin and Dopamine to Modulate Behavior in
Oakes M; Law WJ; Komuniecki R
J Neurosci; 2019 May; 39(21):4142-4152. PubMed ID: 30886012
[No Abstract] [Full Text] [Related]
13. Anandamide and NADA bi-directionally modulate presynaptic Ca2+ levels and transmitter release in the hippocampus.
Köfalvi A; Pereira MF; Rebola N; Rodrigues RJ; Oliveira CR; Cunha RA
Br J Pharmacol; 2007 Jun; 151(4):551-63. PubMed ID: 17435795
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide.
Facchinetti F; Del Giudice E; Furegato S; Passarotto M; Leon A
Glia; 2003 Jan; 41(2):161-8. PubMed ID: 12509806
[TBL] [Abstract][Full Text] [Related]
15. [Cannabinoid applications in glaucoma].
Pinar-Sueiro S; Rodríguez-Puertas R; Vecino E
Arch Soc Esp Oftalmol; 2011 Jan; 86(1):16-23. PubMed ID: 21414525
[TBL] [Abstract][Full Text] [Related]
16. Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta.
O'Sullivan SE; Kendall DA; Randall MD
Eur J Pharmacol; 2005 Jan; 507(1-3):211-21. PubMed ID: 15659311
[TBL] [Abstract][Full Text] [Related]
17. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells.
Chiba T; Ueno S; Obara Y; Nakahata N
J Pharm Pharmacol; 2011 May; 63(5):636-47. PubMed ID: 21492165
[TBL] [Abstract][Full Text] [Related]
18. Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors.
Redmond WJ; Cawston EE; Grimsey NL; Stuart J; Edington AR; Glass M; Connor M
Br J Pharmacol; 2016 Jan; 173(1):115-27. PubMed ID: 26398720
[TBL] [Abstract][Full Text] [Related]
19. The cannabinoid receptor agonists, anandamide and WIN 55,212-2, do not directly affect mu opioid receptors expressed in Xenopus oocytes.
Kracke GR; Stoneking SP; Ball JM; Tilghman BM; Washington CC; Hotaling KA; Johnson JO; Tobias JD
Naunyn Schmiedebergs Arch Pharmacol; 2007 Dec; 376(4):285-93. PubMed ID: 17960365
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of endogenous, phyto and synthetic cannabinoids on thrombogenesis and platelet activity.
Grambow E; Strüder D; Klar E; Hinz B; Vollmar B
Biofactors; 2016 Nov; 42(6):581-590. PubMed ID: 27151562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
